1243 GMT July 05, 2022
Iran has cemented its growing success in the field of biotechnology as new products unveiled to help the country cut its costly imports, Press TV reported.
IRNA said that the biotech products included treatments based on blood plasma, namely the human serum albumin (HAS) and intravenous immunoglobulin (IVIG), developed and commercialized by Medvac, a biopharma company based in Karaj, near Tehran.
Before the development of the blood products, Iran had been forced to pay nearly €60 million each year to pharma companies in Germany and Austria to have blood plasma collected in Iran, refined, and turned into HAS and IVIG vials. The drugs are used in treating complicated blood conditions.
An Iranian-made vaccine used for treatment of human papillomavirus (HPV) was also unveiled on Thursday. The human vaccine, developed by Noyan Biopharma, will rival Gardasil of Merck & Co which is used on a massive scale around the world to prevent cervical cancer.
Another biotech company in the city of Saveh, around 120 kilometers to the southwest of the capital Tehran, announced it had developed the active pharmaceutical ingredient used to manufacture sertraline, a generic anti-depressant, said the report by IRNA.
All the three biotech drugs have been developed and commercialized using funds and support provided by the Iranian government. Some $17 million have been spent on the development of the drugs as well as other biotech projects unveiled on Thursday, said the report, adding that the projects will create 336 permanent jobs.
While unveiling the biotech products, Rouhani hailed Iran’s robust progress in the field of biotechnology. He promised biotech firms in Iran will produce at least four new human vaccines until his government leaves office in August 2021.